A population-based case-control study of oral griseofulvin treatment during pregnancy.
OBJECTIVE
To study the teratogenicity of oral griseofulvin during pregnancy.


METHODS
The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 and the Hungarian Congenital Abnormality Registry between 1970 and 2002 were evaluated.


RESULTS
In total, 38,151 pregnant women who delivered newborn infants without any defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities were included in the study. Seven (0.03%) case and 24 (0.06%) control pregnant women were treated with the griseofulvin (crude odds ratio with 95% confidence interval: 0.49, 0.21-1.13). A teratogenic potential of griseofulvin was not indicated by a comparison of the expected and observed number of different congenital abnormalities. A higher mean birth weight was found in control newborn infants born to mothers with griseofulvin treatment compared with the data of control newborn infants without this treatment. In addition, 55 conjoined twins were evaluated in the data set of the Hungarian Congenital Abnormality Registry, and no conjoined twins had mother with griseofulvin treatment during pregnancy.


CONCLUSIONS
Our data do not indicate a detectable teratogenic risk of oral griseofulvin treatment during pregnancy; however, the numbers of cases and controls were limited. Therefore, international collaboration is needed for the final conclusion.
Czeizel
Andrew E
AE
Foundation for the Community Control of Hereditary Diseases, National Center for Epidemiology, Budapest, Hungary. czeizel@interware.hu
Métneki
Júlia
J
Kazy
Zoltán
Z
Puho
Elisabeth
E
D000014:Abnormalities, Drug-Induced / Q000175:diagnosis / Q000453:epidemiology*; D000284:Administration, Oral; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001724:Birth Weight; D016022:Case-Control Studies; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006118:Griseofulvin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D015994:Incidence; D007231:Infant, Newborn; D016017:Odds Ratio; D011247:Pregnancy; D012016:Reference Values; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment
D000935:Antifungal Agents; D006118:Griseofulvin